Civitas Therapeutics

Civitas Therapeutics was a privately held biopharmaceutical company founded in 2009 (Chelsea/Cambridge, Massachusetts) that developed inhaled therapeutics using the proprietary ARCUS dry-powder pulmonary delivery platform. Its lead program, CVT-301, was an inhaled levodopa therapy for the rapid relief of OFF episodes in Parkinson's disease patients. The company was acquired by Acorda Therapeutics in 2014 for approximately $525 million and no longer operates as an independent entity. It is a life-sciences / drug-development company with no public developer platform, API, SDK, or technical integration surface. Surfaced as a portfolio company of canaan-partners and retained in the API Evangelist network for provenance.

Civitas Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Life Sciences, and Drug Development.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalPharmaceuticalsLife SciencesDrug DevelopmentInhalation TherapyParkinsons DiseaseAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/civitas-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: civitas-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/civitas-therapeutics.png
name: Civitas Therapeutics
description: Civitas Therapeutics was a privately held biopharmaceutical company founded in 2009 (Chelsea/Cambridge, Massachusetts)
  that developed inhaled therapeutics using the proprietary ARCUS dry-powder pulmonary delivery platform. Its lead program,
  CVT-301, was an inhaled levodopa therapy for the rapid relief of OFF episodes in Parkinson's disease patients. The company
  was acquired by Acorda Therapeutics in 2014 for approximately $525 million and no longer operates as an independent entity.
  It is a life-sciences / drug-development company with no public developer platform, API, SDK, or technical integration surface.
  Surfaced as a portfolio company of canaan-partners and retained in the API Evangelist network for provenance.
url: https://raw.githubusercontent.com/api-evangelist/civitas-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Acorda Therapeutics
x-acquired-year: 2014
x-api-surface: none
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Life Sciences
- Drug Development
- Inhalation Therapy
- Parkinsons Disease
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1